Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 3Recruiting 2Unknown 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 20Lymphoma 17Neoplasm Metastasis 14Leukemia, Myeloid, Acute 12Pancreatic Neoplasms 9Breast Neoplasms 9Ovarian Neoplasms 8Melanoma 8Lung Neoplasms 8Colorectal Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Glioma 7Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Neuroblastoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Endometrial Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Ependymoma 5Burkitt Lymphoma 5Wilms Tumor 4Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

Carboplatin 15durvalumab 14Etoposide 14pembrolizumab 9atezolizumab 9Cisplatin 9Topotecan 8Nivolumab 7Specimen Handling 6olaparib 4berzosertib 4Temozolomide 4Magnetic Resonance Spectroscopy 4AMG 757 4tremelimumab 3Radiotherapy 3Radiosurgery 3PM 01183 3Ipilimumab 3Docetaxel 3Biopsy 3niraparib 2lenvatinib 2cabozantinib 2Platinum 2Irinotecan 2Fulvestrant 2veliparib 1tislelizumab 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Carcinoma × Biopsy × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

National Cancer Institute (NCI)

Phase 2 Active not recruiting
104 enrolled 22 charts
Thoracic

Small Cell Lung Carcinoma

NCT05353439 2026-05-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡